Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study of androgenic alopecia patients reports that stress was associated with AGA in both men and women, with notable findings differing by gender, age, and AGA type.

This study found that low-level light therapy and fractional lasers are effective and safe treatments for androgenetic alopecia, with the greatest improvements in hair density and thickness seen in combination therapies.

This study suggests that low proliferation rates in bald areas of androgenetic alopecia patients, along with persistent inflammatory infiltrate, may lead to follicular miniaturization and fibrosis.

This study found that melatonin-loaded vitamin C-based nanovesicles improved hair thickness, density, and reduced hair loss in patients with androgenic alopecia more effectively than melatonin solution.

This source establishes prior art for treating androgenic alopecia and sexual dysfunction by restoring gap-junction-mediated connectivity in tissue networks, highlighting a mechanism independent of commonly targeted pathways.

This review article examines current drugs for androgenetic alopecia, focusing on their mechanisms and clinical efficacy, noting that while finasteride and minoxidil are commonly approved treatments, new drugs targeting different pathogenic pathways have emerged, offering a broader understanding and reference for AGA treatment options.

This discussion reviews the shift in pharmaceutical strategy towards evidence-based and structure-guided drug development, highlighting ongoing challenges and efforts in computer-aided drug design without presenting new clinical results.

This study found that a 3 mm margin around the prostate CTV may be adequate if accompanied by frequent imaging, but superior-inferior displacements were notably greater than in other directions.

This review discusses genetic contributions to androgenetic alopecia and proposes focusing on candidate genes in genome-wide association studies, but it reports no new clinical results.

This review discusses the application of transdermal drug delivery systems for androgenetic alopecia and explores new technologies to enhance drug penetration but reports no clinical results.

This study outlines a hair regrowth treatment targeting hair follicle stem cells, 5-alpha reductase pathway, and microinflammation using PDGF and VEGF, but reports no clinical results.

This paper reviews the role of endoplasmic reticulum stress and the unfolded protein response in Hutchinson-Gilford progeria syndrome-related atherosclerosis, especially in vascular smooth muscle cells, but reports no clinical findings; intervention in these pathways is suggested as a potential therapeutic strategy.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

This review explores the causes and diagnostic methods for androgenetic alopecia but reports no new clinical results, underlining the importance of developing new treatments.

This review discusses therapeutic options for androgenetic alopecia, noting that while antiandrogen treatments prevent further hair loss and promote some regrowth, dramatic results are rare.

This study found that while the new cytopurine/pentadecanoic glyceride topical solution significantly improved total hair and daily shed hair counts in AGA patients, it did not show significant differences compared to placebo in other measures.

In this study, the researchers demonstrated an automatic alignment method for beams in an electron pumped excimer laser system that achieved high precision and accuracy, with a reported alignment accuracy of 0.63μrad.

This article discusses the mixed perceptions and potential profitability of PRP therapy in hair treatment, but does not report new clinical results.

This study found that male patients with androgenetic alopecia had higher serum levels of Zinc Alpha 2 Glycoprotein than healthy controls, suggesting its potential role in the disease's pathophysiology.

This study reports that low-level light therapy and fractional lasers are effective and safe treatments for androgenetic alopecia, with more pronounced results when combined with other therapies.

This study presents a new model for the progression of androgenetic alopecia, suggesting that the loss of attachment between the bulge's stem cells and the arrector pili muscle may contribute to irreversible hair miniaturization.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

In this case report, a 28-year-old male with androgenetic alopecia showed improved hair density and shaft thickness after four monthly sessions of autologous growth factor concentrate injections, with no adverse effects and high patient satisfaction, suggesting the treatment’s promise as a safe and effective option.

This study found that individuals with androgenetic alopecia experience significantly higher symptoms of anxiety, depression, and stress compared to controls, along with reduced self-esteem and life satisfaction, highlighting the importance of addressing psychological well-being in clinical treatments.

This paper proposes a theory explaining how the normal anabolic effects of androgens lead to structural changes and hair follicle miniaturization, contributing to androgenic alopecia.

This study found a positive correlation between androgenetic alopecia severity and enlarged prostate size, with more severe cases showing a higher likelihood of prostate enlargement.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

In clinical studies, inhibiting androgen receptor expression using CosmeRNA ARI SAMiRNA micelles effectively treated androgenetic alopecia by significantly increasing hair growth, as reported in this research.

In this study, researchers administered injectable platelet-rich fibrin (i-PRF) to 30 patients with androgenetic alopecia, finding an 80% response rate after 6 months, with improved hair density and reduced scalp symptoms, while reporting minimal adverse reactions.